Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NLS Pharmaceutics ( (NLSP) ) has shared an update.
NLS Pharmaceutics and Kadimastem, in collaboration with iTolerance, have submitted a request for a Pre-IND meeting with the FDA for iTOL102, a novel treatment for Type 1 Diabetes. This milestone follows a successful INTERACT meeting and marks significant progress in the development of a therapy that combines allogenic human stem cell-derived pancreatic islets with an immunomodulator. The companies believe the innovative treatment could potentially cure Type 1 Diabetes, reducing the need for lifelong immunosuppression. The merger between NLS Pharmaceutics and Kadimastem, anticipated to close by January 2025, aims to enhance the combined company’s growth and expand its therapeutic pipeline.
More about NLS Pharmaceutics
NLS Pharmaceutics is a global biopharmaceutical company focused on developing innovative therapies for rare and complex central nervous system disorders. Kadimastem is a clinical-stage cell therapy company that develops allogeneic cell products for neurodegenerative diseases and diabetes, with its lead product in clinical development for ALS. iTolerance is a regenerative medicine company creating technologies to facilitate cell therapy without lifelong immunosuppression, aiming to cure diseases like Type 1 Diabetes.
YTD Price Performance: -91.53%
Average Trading Volume: 354,591
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.94M
For an in-depth examination of NLSP stock, go to TipRanks’ Stock Analysis page.
